TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06555094

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Ecological momentary assessment (EMA)
Description: 4x/day brief smartphone-based EMA surveys assessing negative emotions and STBs

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment as usual (TAU)
Description: TAU (or usual care) during hospitalization and the 28-day post-discharge period

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as usual (TAU)
Description: TAU (or usual care) during hospitalization and the 28-day post-discharge period

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief skills sessions plus EMI skills practice prompts
Description: (1) Three brief treatment sessions delivering core cognitive behavioral therapy (CBT) skills (mindful emotion awareness, cognitive flexibility, and changing emotional behaviors) (during hospitalization), (2) a discretionary booster session to reinforce treatment session content (that may be offered after discharge via either phone or telehealth), and (3) ecological momentary intervention (EMI) prompts to engage in guided skills practice exercises via smartphone
Study: NCT05227274

Intervention type: OTHER
Intervention: Items completion with or without a MFM-Play
Description: Patients will completed 3 MFM during the follow-up, two times using the MFM-Play, and one without the MFM-Play Delay between each MFM completion will be 1 month ± 15 days
Study: NCT06178510

Intervention type: DEVICE
Group type: OTHER
Intervention: INTELLiVENT-ASV.
Description: INTELLiVENT-ASV® is a closed-loop ventilation mode that automatically adjusts respiratory rate and tidal volume according to the oxygen and ventilatory patient needs
Study: NCT05058872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel/ethinyl estradiol
Description: Levonorgestrel 0.15mg/ethinyl estradiol 0.03mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT05595473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RZ-001 Dose 1
Description: RZ-001 Dose 1 and VGCV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RZ-001 Dose 2
Description: RZ-001 Dose 2 and VGCV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RZ-001 Dose 3
Description: RZ-001 Dose 3 and VGCV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RZ-001 Dose 4
Description: RZ-001 Dose 4 and VGCV
Study: NCT06249126

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Primary Fusion (Open Reduction Internal Fixation (ORIF) + Primary Subtalar Arthrodesis (PSTA)
Description: Definitive fixation by joint fusion

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Open Reduction Internal Fixation (ORIF) only
Description: Definitive fixation with plates and screws
Study: NCT06372639

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trans-Cranial Magnetic Stimulation
Description: Brain stimulation by the TMS device will be given after a deliberate memory re-activation, using repetitive pulses at 1Hz frequency for 15 minutes, the target area will be determined based on an fMRI scan in the resting state of the subject.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Trans-Cranial Magnetic Stimulation
Description: Brain stimulation by the TMS device will be given after a deliberate memory re-activation, using repetitive pulses at 1Hz frequency for 15 minutes, the target area will be determined based on an fMRI scan in the resting state of the subject.
Study: NCT05826353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ripasudil
Description: K-321 ophthalmic solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo ophthalmic solution
Study: NCT05219344

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue flossing
Description: After the standardized warm-up, participants will be instructed to stand still with their legs shoulder-width apart. The floss band (1.3 mm thick, 50 mm wide, 2 meters long, and strength level 3), consisting of a thick elastic latex band (COMPRE Floss, Sanctband), will be applied bilaterally around the distal third of the thigh. The applied pressure will be individualized by thigh circumferences, whereas low target pressure was chosen for this study, showing potential to elicit the most beneficial outcomes following flossing. The pressure will be monitored by the PicoPress device, which was placed at the middle distance of the application of the floss band to ensure that the entire surface of the pressure sensors was always completely covered. The flossing will be applied for 2 minutes with 2 minutes rest between sets. During flossing application subjects will be instructed to conduct 10 deep squats followed by 15 repetitions of knee extensions without added weight.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tissue flossing
Description: After the standardized warm-up, participants will be instructed to stand still with their legs shoulder-width apart. The floss band (1.3 mm thick, 50 mm wide, 2 meters long, and strength level 3), consisting of a thick elastic latex band (COMPRE Floss, Sanctband), will be applied bilaterally around the distal third of the thigh. The applied pressure will be individualized by thigh circumferences, whereas low target pressure was chosen for this study, showing potential to elicit the most beneficial outcomes following flossing. The pressure will be monitored by the PicoPress device, which was placed at the middle distance of the application of the floss band to ensure that the entire surface of the pressure sensors was always completely covered. The flossing will be applied for 2 minutes with 2 minutes rest between sets. During flossing application subjects will be instructed to conduct 10 deep squats followed by 15 repetitions of knee extensions without added weight.
Study: NCT05463666

Intervention type: OTHER
Intervention: Rheumatoid arthritis
Description: A diagnosis of rheumatoid arthritis.
Study: NCT05525715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2mg QY201 tablets or 2mg QY201 placebo,BID
Description: 2mg QY201 tablets or 2mg QY201 placebo,BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5mg QY201 tablets or 5mg QY201 placebo,BID
Description: 5mg QY201 tablets or 5mg QY201 placebo,BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10mg QY201 tablets or 10mg QY201 placebo,QD
Description: 10mg QY201 tablets or 10mg QY201 placebo,QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10mg QY201 tablets or 10mg QY201 placebo,BID
Description: 10mg QY201 tablets or 10mg QY201 placebo,BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 15mg QY201 tablets or 15mg QY201 placebo,BID
Description: 15mg QY201 tablets or 15mg QY201 placebo,BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20mg QY201 tablets or 20mg QY201 placebo,BID
Description: 20mg QY201 tablets or 20mg QY201 placebo,BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5mg QY201 tablets，BID
Description: 5mg QY201 tablets，BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10mg QY201 tablets，BID
Description: 10mg QY201 tablets，BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20mg QY201 tablets，BID
Description: 20mg QY201 tablets，BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QY201 placebo，BID
Description: QY201placebo，BID
Study: NCT04760457

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant placement with flapped surgery
Description: Four mini implants will be placed reflecting a flap.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant placement with flapped surgery
Description: Four mini implants will be placed reflecting a flap.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant placement with flapless surgery
Description: Four mini implants will be placed without reflecting a flap.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant placement with flapless surgery
Description: Four mini implants will be placed without reflecting a flap.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant immediate loading
Description: Four mini implants will be immediately loaded.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant immediate loading
Description: Four mini implants will be immediately loaded.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant delayed loading
Description: Four mini implants will be loaded after a 6-week healing period.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant delayed loading
Description: Four mini implants will be loaded after a 6-week healing period.
Study: NCT06281002

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional impression stone casts digitization
Description: Nine conventional physical open tray impressions will be poured into a hard dental stone to obtain nine definitive implant casts with conventional implant analogs to act as a reference comparator.~Impressions will be digitized to reference STL files.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: digital scanning with coupled scanning aiding device
Description: Nine optical impressions will be obtained while additional geometric scanning aids are coupled with the scan bodies to get nine CAD/CAM 3D-printed polymer casts with digital implant analogs.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Implant Model assessment of accuracy
Description: The nine STL files of optical scanning will serve as reference data for comparison with the digitized DIMs to evaluate the accuracy of representation of the actual position of implants in the software.
Study: NCT05257213

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin solution
Description: 3 ml saline solution containing 5000 IU heparin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-adhesion barrier gel
Description: 2 ml biodegradable barrier gel containing sodium hyaluronate (10 mg/ml), sodium chloride (8.5 mg/ml), disodium hydrogen phosphate (0.34mg/ml), sodium dihydrogen phosphate (0.14 mg/ml) and water for injection (QS to weight).
Study: NCT04846478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: capsule, taken by mouth, once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: capsule, taken by mouth, once a day
Study: NCT06493838

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intravenous 50 mL of saline injection of 0.9% after umbilical cord clamping.
Description: intravenous 50 mL of saline injection of 0.9% after umbilical cord clamping.
Study: NCT04846478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: orally as a tablet twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: orally as a tablet twice daily.
Study: NCT05667402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBF regimen
Description: The subjects receive TBF conditioning regimen (Thiotepa, Busulfan, Fludarabine) before allo-HSCT.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: modified BuCY2 regimen
Description: The subjects receive modified BuCY2 conditioning regimen (Busulfan, Cytarabine, ATG, Cyclophosphamide, CCNU) before allo-HSCT.
Study: NCT06535776

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matrix Rhythm Therapy
Description: Individuals in this group will be taught home exercises face-to-face in a single session as in the home-based exercise group and will be asked to perform the exercises themselves at home for 3 non-consecutive days a week for 6 weeks. In addition to home-based exercises, a total of 12 sessions of face-to-face matrix rhythm therapy will be performed, 2 non-consecutive days a week for 6 weeks. Matrix rhythm therapy applications will be applied by a specialist physiotherapist who has received training with the matrix rhythm therapy vibromassage device.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-based Exercise
Description: Home-based exercise program will be explained to patients diagnosed with axSpA by a physiotherapist. All exercises will be repeated with the physiotherapist and explained until understood. Patients will be asked to perform these exercises on their own 3 non-consecutive days a week for 6 weeks. Patients will be called by the physiotherapist on each exercise day and their home exercises will be monitored and recorded in the exercise tracking chart created for each patient. In addition, the patients will be given an exercise follow-up chart and they will be asked to fill in the existing chart and submit it at the end of the 6-week training.
Study: NCT06493838

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine 20μg/kg (Neostigmine Methylsulphate 0.5 mg, Amriya Pharm.Ind.) and atropine 0.01 mg/kg (diluted in 50 ml saline; 0.9% for 10 min) following umbilical cord clamping.
Description: Neostigmine 20μg/kg (Neostigmine Methylsulphate 0.5 mg, Amriya Pharm.Ind.) and atropine 0.01 mg/kg (diluted in 50 ml saline; 0.9% for 10 min) following umbilical cord clamping.
Study: NCT06535776

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based Exercise
Description: Home-based exercise program will be explained to patients diagnosed with axSpA by a physiotherapist. All exercises will be repeated with the physiotherapist and explained until understood. Patients will be asked to perform these exercises on their own 3 non-consecutive days a week for 6 weeks. Patients will be called by the physiotherapist on each exercise day and their home exercises will be monitored and recorded in the exercise tracking chart created for each patient. In addition, the patients will be given an exercise follow-up chart and they will be asked to fill in the existing chart and submit it at the end of the 6-week training.
Study: NCT05521282

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Treatment group
Description: Based on the basic treatment, Qianglidingxuan Tablets were given 6 tablets/time, 3 times a day, and warm water was given for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment group
Description: Based on the basic treatment, Qianglidingxuan Tablets were given 6 tablets/time, 3 times a day, and warm water was given for 12 weeks.
Study: NCT05882331

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extracorporeal photopheresis
Description: ECP is initiated on study inclusion day by Therakos Cellex system, according to manufacturers' instructions. Each patient receives two ECP cycles for 2 weeks, each consisting of two sessions on consecutive days per week (alltogether four sessions), through a peripheral or central venous route. Cycles 1 and 2 are separated by 5 consecutive days. One ECP session takes \~3 hours, and is separated into 4 phases. On priming, the system performes a series of calibrations to ensure proper operation. During collection, 1500 ml of whole blood is processed to collect a concentrated buffy coat containing white blood cells, while other cells and plasma are reinfused. During the photoactive phase, a prescribed dose of 8-methoxypsoralen is added to the buffy coat, which is then circulated through ultraviolet-A photoactivation. During reinfusion phase, treated cells are automatically reinfused to the patient.
Study: NCT04891861

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: Direct Oral Anticoagulation all at label dose and frequency

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: Direct Oral Anticoagulation all at label dose and frequency
Study: NCT06012695

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBM-BMX Capsule
Description: Each capsule contains 100 mg of the active ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBM-BMX Capsule
Description: Each capsule contains 100 mg of the active ingredient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: TMZ will be administered orally at a 75 mg/m2 dose daily during concomitant therapy. In the maintenance period, days 1-5 of each cycle will be administered 150-200 mg/m2.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Standard radiotherapy
Description: A total dose of 60 Gy will be administered in 6 weeks.
Study: NCT06015334

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cataract surgery with implantation of intraocular lens
Description: Cataract surgery with implantation of bilateral trifocal IOL (TECNIS Synergy) implantation or bilateral monofocal IOL (Tecnis monofocal) with monovision.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cataract surgery with implantation of intraocular lens
Description: Cataract surgery with implantation of bilateral trifocal IOL (TECNIS Synergy) implantation or bilateral monofocal IOL (Tecnis monofocal) with monovision.
Study: NCT04776876

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat Ethyl
Description: Given PO
Study: NCT05249764

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised Home Based Exercise Training
Description: Exercise program was prepared based on WHO, American College of Sports Medicine (ACSM), Geriatrics Physiotherapists Association and Otago exercise program for the exercise group. The older adults are given individual supervised exercise training in their own homes for eight weeks, 3 days a week and 45 minutes a day, by a physiotherapist according to social distance rules. This exercise training consists of a program that includes strengthening, flexibility, aerobic and balance exercises. Each exercise is started with eight repetitions and each week will be increased by two repetitions. In case of fatigue, a rest is given. Brochures are also be prepared for the exercises. Before each session, individuals performed warm-up exercises for 5 minutes. At the end of the session, individuals performed cooling exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unsupervised stretching and breathing exercises
Description: Individuals in the control group are performing stretching exercises for proximal extremity muscles for 15 minutes 3 times a week for eight weeks. The participants also perform breathing exercises for 5 minutes a day.
Study: NCT06529601

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAD/CAM mandibular fixed retainer
Description: Keeppy is a Class IIa custom-made medical device manufactured by Digital Service Leone s.r.l. - via Pratese 160/b, Florence, Italy. The Keeppy is an individualized fixed retainer, made of a Nickel-free Chrome Cobalt alloy, produced with a CAD-CAM procedure starting from a digital impression made with an intraoral optical scanner (3 Shape), which allows a perfect adaptation to the lingual surfaces of the 6 lower anterior teeth on which it is bonded. The device is characterized by the presence of applicators that can be placed temporarily on the buccal surface of the canines, which facilitate the clinician in the precise application of the device and which are removed as soon as the bonding phase of the retainer is complete. Bonding is performed using classic composite resins following a preparation phase of the lingual surface of the tooth consisting of the application of etchant (37% orthophosphoric acid) for 30 seconds and adhesive (primer-bonding).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional mandibular fixed retainer
Description: The standard control device, which is among the most commonly used in routine clinical practice, consists of a steel braided wire. The device selected for the Class IIa investigation is the Ortho Flex Tech manufactured by Reliance Orthodontic Products, Inc. 1540 West Thorndale Ave. Itasca, IL 60143 USA. The Ortho Flex Tech steel braided wire is manually shaped by the clinician and cut with a wire cutter so that it has the proper length to extend over the 6 dental elements. Once the correct length has been defined, it is then held in place on the lingual surface of the teeth by the use of 2 interdental wires passing doubly through the interdental area (between the lateral incisor and canine on one side and the other). This allows the device to be bonded using composite resin after etching the lingual surfaces of the lower anterior teeth.
Study: NCT06403033

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mini-implant-supported Twin-Block
Description: Mini-implants will support the Twin-Block appliance during the functional treatment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Twin-Block
Description: This is the main appliance that will be used to correct the Class II deformity.
Study: NCT06465121

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral intravenous catheterization performed with ultrasound guidance by a trained nurse
Description: Intravenous catheterization using ultrasound-guidance to allow real-time visualization of target veins in pediatric patients with difficult intravenous access
Study: NCT06329336

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Emotional Competence for Children and Parents
Description: This preventive parenting intervention combines behavioral parenting and mindfulness-based well-being practices to support effective parenting.
Study: NCT04964401

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic paravertebral block vs Erector spinae plane block
Description: Thoracic paravertebral block and erector spinae plane block will be performed unilaterally, under US guidance, before the surgical operation, after the induction of anesthesia, when the patient is placed in the lateral decubitus position.
Study: NCT05987137

Intervention type: OTHER
Intervention: No intervention is being administered.
Description: No intervention is being administered.

Intervention type: OTHER
Intervention: No intervention is being administered.
Description: No intervention is being administered.

Intervention type: OTHER
Intervention: No intervention is being administered.
Description: No intervention is being administered.

Intervention type: OTHER
Intervention: No intervention is being administered.
Description: No intervention is being administered.
Study: NCT04334811

Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic ablative radiotherapy
Description: Stereotactic ablative radiotherapy (SAbR) delivers of a potent, ablative or nearly ablative dose of radiation in oligofractions (ie, five or fewer fractions) primarily to create a compact dose delivered accurately to the intended target with steep gradients in all directions (geometric avoidance) and avoid damaging normal tissues.